Rather than seeking to grab the attention of patients and winning support from individual physicians, the Swiss pharmaceutical giant is focusing on the people who run large hospital systems. Its pitch: A large-scale rollout of the drug, called Leqvio, could avert thousands of heart attacks and strokes. Despite heart disease being the No. 1 killer in the U.S., the strategy could prove challenging to pull off.
Read the source article at Wealth Creation Investing